{
    "clinical_study": {
        "@rank": "124268", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with normal renal function: healthy normal adult subjects with an eGFR \u2265 90 mL/min/1.73m2."
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with mild renal impairment: adult subjects with a eCFR \u2265 90 mL/min/1.73m2."
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Experimental", 
                "description": "Moderate renal impairment: adult subjects with an eGFR between \u226530 - \u2264 59 mL/min/1.73m2."
            }, 
            {
                "arm_group_label": "Group 4", 
                "arm_group_type": "Experimental", 
                "description": "Severe renal impairment: adult subjects with an eGFR \u2264 29 mL/min/1.73m2, not on dialysis."
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective of the trial is to compare the pharmacokinetics of a 60 mg dose of\n      cabozantinib in adult subjects with impaired renal function compared with healthy adult\n      subjects. Another objective is to assess the safety and tolerability of cabozantinib in\n      these adult subjects."
        }, 
        "brief_title": "A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Healthy", 
            "Renal Impairment"
        ], 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body weight must be \u2265 50 kg and < 130 kg with a BMI \u2264 38.0 (kg/m2).\n\n          -  Must use acceptable form of birth control during the course of the study   and for 3\n             months following the single dose of study drug.\n\n          -  Female subjects of childbearing potential must have a negative pregnancy test at\n             screening and check-in.\n\n          -  Negative test for HIV; hepatitis A, B, and C.\n\n          -  Must have adequate vital sign reads at screening and check-in.\n\n          -  Must be able to comply with dietary and fluid restrictions required for the study.\n\n        Exclusion Criteria:\n\n          -  History of medical or surgical conditions that would interfere with GI absorption,\n             distribution, metabolism, or excretion of the study drug.\n\n          -  Recent clinical evidence of pancreatic injury.\n\n          -  Recent use of drugs known to significantly inhibit or induce P450 CYP3A4 enzymes.\n\n          -  Previous diagnosis of malignancy.\n\n          -  Unwilling to forgo use of any over-the-counter or non-prescription preparations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01761773", 
            "org_study_id": "XL184-017"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group 1", 
                "Group 2", 
                "Group 3", 
                "Group 4"
            ], 
            "description": "3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.", 
            "intervention_name": "cabozantinib", 
            "intervention_type": "Drug", 
            "other_name": "XL184"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neptune", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07753"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "AUC, Cmax, tmax, kel, t1/2, CL/F, V/F and fu as measure of a single oral 60 mg dose of cabozantinib in adults with impaired renal function compared with healthy subjects matched for age, gender, and body mass index (BMI).\nSubjects will receive a single oral 60 mg dose of cabozantinib on Day 1 and then undergo periodic assessments Days 1 - 8 following this single dose, as well as on the mornings of Days 11, 13, 15, 18, 21, 22.", 
            "measure": "Pharmacokinetics", 
            "safety_issue": "No", 
            "time_frame": "Days 1 - 8 as well as the morning of Days 11, 13, 15, 18, 21, 22."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01761773"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Number of participants with adverse events, serious adverse events, and laboratory abnormalities as a measure of the safety and tolerability of a single oral 60 mg dose in adult subjects with impaired renal function and in healthy adult subjects.", 
            "measure": "Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Days 1 - 8 and Days 11, 13, 15, 18, 21, 22."
        }, 
        "source": "Exelixis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Exelixis", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}